Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
Danie du Plessis, Executive Vice President of International Medical Affairs, Kyowa Kirin, commented: “The studies presented at EORTC-CLTG demonstrate our long-term commitment to expand the evidence base for the effectiveness of mogamulizumab in real-world settings.
- Danie du Plessis, Executive Vice President of International Medical Affairs, Kyowa Kirin, commented: “The studies presented at EORTC-CLTG demonstrate our long-term commitment to expand the evidence base for the effectiveness of mogamulizumab in real-world settings.
- OMEGA, a completed, retrospective, real-world, non-interventional observational study, described real-world effectiveness and tolerability of mogamulizumab in patients with MF and SS.
- Across all three trials no new safety signals were seen.
- The real-world evidence being generated by Kyowa Kirin raises the standard of information available to those involved in treating mycosis fungoides and Sézary syndrome helping to inform decisions that support optimal patient care.”